Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

<i>KRAS</i> mutations are one of the most common oncogenic drivers in non-small cell lung cancer (NSCLC) and in lung adenocarcinomas in particular. Development of therapeutics targeting KRAS has been incredibly challenging, prompting indirect inhibition of downstream targets such as MEK...

Full description

Bibliographic Details
Main Authors: Elisa Baldelli, Emna El Gazzah, John Conor Moran, Kimberley A. Hodge, Zarko Manojlovic, Rania Bassiouni, John D. Carpten, Vienna Ludovini, Sara Baglivo, Lucio Crinò, Fortunato Bianconi, Ting Dong, Jeremy Loffredo, Emanuel F. Petricoin, Mariaelena Pierobon
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Genes
Subjects:
non-small cell lung cancer
KRAS
zygosity
drug target
reverse-phase protein microarray
Online Access:https://www.mdpi.com/2073-4425/12/9/1402

Internet

https://www.mdpi.com/2073-4425/12/9/1402

Similar Items